Phibro Animal Health Corporation - Class A Common Stock (PAHC)
39.44
-0.28 (-0.70%)
NASDAQ · Last Trade: Jan 11th, 6:52 PM EST
Detailed Quote
Previous Close
39.72
Open
39.71
Bid
37.00
Ask
41.00
Day's Range
39.18 - 40.20
52 Week Range
16.16 - 46.42
Volume
163,725
Market Cap
1.20B
PE Ratio (TTM)
23.62
EPS (TTM)
1.7
Dividend & Yield
0.4800 (1.22%)
1 Month Average Volume
250,280
Chart
About Phibro Animal Health Corporation - Class A Common Stock (PAHC)
Phibro Animal Health Corporation is a global company that focuses on providing a wide range of animal health products and services. It develops, manufactures, and markets products aimed at improving the health and productivity of livestock and poultry, which includes vaccines, diagnostic tools, and nutritional products. By leveraging its expertise in science and technology, the company seeks to enhance animal well-being and optimize food safety and quality throughout the agricultural industry. Additionally, Phibro is committed to innovation and sustainability, striving to meet the evolving needs of farmers and the broader food supply chain. Read More
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) fell short of the markets revenue expectations in Q1 CY2026, with sales flat year on year at $347.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.46 billion at the midpoint. Its non-GAAP profit of $0.63 per share was 8.3% below analysts’ consensus estimates.
Phibro Animal Health Corporation (Nasdaq: PAHC) (the “Company” or “Phibro”) today announced a leadership transition that will support the Company’s continued growth and long-term strategic direction. At the end of this fiscal year, effective July 1, 2026, Jack Bendheim, current Chairman, Chief Executive Officer and President of Phibro will take on a new managerial role as Executive Chairman and Daniel (Dani) Bendheim will assume the role of Chief Executive Officer and President of Phibro. Jack Bendheim will continue to serve as the Chairman of the Board of Directors of the Company.
Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its updated financial guidance for the year ending June 30, 2026.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025.
Discover how Phibro Animal Health (PAHC) combines strong technical trends with accelerating earnings and revenue growth, signaling a potential high-momentum investment.
Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation.
Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time.
Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals.
Phibro Animal Health (PAHC) stock shows strong technical & fundamental momentum, meeting Minervini's Trend Template with high growth in earnings and sales.
Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.
Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026.
